Difference between revisions of "SMARCB1"

From Libre Pathology
Jump to navigation Jump to search
m (Michael moved page INI1 to SMARCB1: rename to official name - also used by WP)
Line 15: Line 15:
| Other      =
| Other      =
}}
}}
'''SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily B, member 1''', commonly abbreviated '''SMARCB1''' (or '''INI1''' or '''BAF47'''), is a diagnostic [[immunostain]], because nuclear staining is lost in some specific types of cancer shown below.
'''SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily B, member 1''', commonly abbreviated '''SMARCB1''', is a diagnostic [[immunostain]], because nuclear staining is lost in some specific types of cancer shown below.
 
It is also known as '''INI1''' and '''BAF47'''.


==Negative==
==Negative==

Revision as of 03:41, 15 March 2016

SMARCB1
Immunostain in short

INI1-ve in AT/RT.
Abbreviation SMARCB1, BAF47
Normal staining pattern nuclear staining
Positive any healthy tissue
Negative AT/RT, renal rhabdoid tumour, extrarenal malignant rhabdoid tumour, atypical teratoid/rhabdoid tumour, epithelioid sarcoma

SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily B, member 1, commonly abbreviated SMARCB1, is a diagnostic immunostain, because nuclear staining is lost in some specific types of cancer shown below.

It is also known as INI1 and BAF47.

Negative

See also

References

  1. Hornick, Jason (2009). "Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma". American Journal of Surgical Pathology.
  2. Jackson EM, Sievert AJ, Gai X et al. (March 2009). "Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors". Clin. Cancer Res. 15 (6): 1923–30.
  3. Bishop, JA.; Antonescu, CR.; Westra, WH. (Sep 2014). "SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract.". Am J Surg Pathol 38 (9): 1282-9. doi:10.1097/PAS.0000000000000285. PMID 25007146.
  4. Hasselblatt, M.; Isken, S.; Linge, A.; Eikmeier, K.; Jeibmann, A.; Oyen, F.; Nagel, I.; Richter, J. et al. (Feb 2013). "High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors.". Genes Chromosomes Cancer 52 (2): 185-90. doi:10.1002/gcc.22018. PMID 23074045.